Xyrem sodium oxybate regulatory update

The FDA extended by 90 days the priority review of ORPH's NDA for Xyrem, an oral solution based on gamma hydroxybutyrate (GHB), to treat cataplexy and excessive daytime sleepiness associated with narc...